An FDA advisory panel on Bristol Myers Squibb Opdivo and Merck Keytruda will examine if PD-L1 tumor expression should limit ...

Improved disease-free survival seen among patients with high-risk muscle-invasive urothelial carcinoma after radical surgery.

Is there any difference in efficacy with Keytruda (pembrolizumab) on three-week intervals versus six-week intervals? No. In ...

PDS Biotechnology's HPV-directed immunotherapy is sparking optimism in the biotech industry. Click here to find out why I am ...

Finally, let's turn to the New England Journal of Medicine. Speaking of closing the loop, this is the final analysis of overall survival with pembrolizumab in early-stage triple-negative breast cancer ...

In head-to-head clinical trial, Chinese firm Akeso’s ivonescimab beat top-selling drug pembrolizumab sold as Keytruda by ...

For patients with early-stage triple-negative breast cancer, neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant ...

Aethlon's Hemopurifier® is a clinical stage immunotherapeutic device designed to combat cancer. Read the full article at Investorideas.com According to News-Medical.net, "Immunotherapy, which works ...

Aethlon Medical Granted Full Ethics Approval from the Medanta Institutional Ethics Committee for a Safety, Feasibility, and ...

Investorideas.com ( a go-to investing platform, releases the second of a two-part series looking at news and developments for the treatment of cancer and solid tumors focusing on immunotherapy, ...

The FDA has approved Keytruda (pembrolizumab) in combination with chemotherapy as first-line treatment for adults with malignant pleural mesothelioma.